Merck Announces Collaboration with Mersana Therapeutics to Develop Novel Immunostimulatory Antibody-Drug Conjugates

2022年12月23日 11:07:54 来自: (0)参与

Not intended for UK-, US- or Canada-based media

Collaboration complements Merck’s internal expertise and in-house ADC approach
Companies focused on discovering novel STING-agonist ADCs for up to two targets leveraging Mersana’s proprietary Immunosynthen platform to conjugate proprietary antibodies from Merck
Merck gains exclusive license; Mersana to receive $30 million upfront payment, up to $800 million in development, regulatory and commercial milestones, as well as royalties on net sales

DARMSTADT, Germany -- (BUSINESS WIRE) --

Merck, a leading science and technology company, today announced a research collaboration and commercial license agreement with Mersana Therapeutics, Inc., Cambridge, Massachusetts, USA to discover novel antibody-drug conjugates (ADCs) leveraging Mersana’s proprietary Immunosynthen STING-agonist ADC platform, directed against up to two targets. The Immunosynthen platform is designed to generate systemically administered ADCs that locally activate STING signaling in both tumor-resident immune cells and in antigen-expressing tumor cells, unlocking the anti-tumor potential of innate immune stimulation.

“Building on our deep expertise and portfolio of two clinical and nine preclinical assets in the ADC space, we are focused on the discovery of next-generation state-of-the-art ADC drugs,” said Paul Lyne, Head of Research Unit Oncology at the Healthcare business sector of Merck. “An approach that can directly target the tumor microenvironment with an immunomodulatory ADC has the potential to bring the benefits of this immunotherapy to a broader group of patients. This collaboration with Mersana to design novel immunostimulatory ADCs that can harness the potential of the STING pathway is an ideal complement to our innovation in this area.”

The STING pathway is a fundamental means of generating innate immune response that can lead to anti-tumor activity and immunological memory. Mersana has generated preclinical data demonstrating Immunosynthen’s ability to enable highly targeted STING activation within both tumor cells and tumor resident myeloid cells while avoiding unwanted systemic effects.

“We are pleased to be partnering with Merck in a collaboration designed to extend the reach of our Immunosynthen platform and bring novel new product candidates forward with the potential to benefit patients,” said Anna Protopapas, President and Chief Executive Officer of Mersana Therapeutics.

Under the terms of the agreement, Mersana will develop novel ADC product candidates against up to two targets utilizing its Immunosynthen platform to conjugate proprietary antibodies from Merck.

Mersana will receive an upfront payment of $30 million. Mersana is also eligible to receive reimbursement of certain costs, up to $800 million in potential regulatory, development and commercial milestone payments, and up to low double-digit percentage royalties on worldwide net sales of any approved ADCs developed under the agreement.

All Merck press releases are distributed by e-mail at the same time they become available on the Merck website. Please go to www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.

About Merck

Merck, a leading science and technology company, operates across life science, healthcare and electronics. More than 60,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2021, Merck generated sales of € 19.7 billion in 66 countries.

Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as MilliporeSigma in life science, EMD Serono in healthcare, and EMD Electronics in electronics.  

View source version on businesswire.com: https://www.businesswire.com/news/home/20221219005604/en/

CONTACT:

Your Contacts  
Media Relations  
gangolf.schrimpf@merckgroup.com  
Phone: +49 151 1454-0501  
 
Investor Relations  
investor.relations@merckgroup.com  
Phone: +49 6151 72-3321 

相关新闻
天猫网友:俄徹底心灰
评论:警察说:"你不知道开车不让打电话吗?"我一脸疑惑的说:"我没打电话呀?.....我发短信来着!"

网易网友:潇洒 小姐 Seve°
评论:感情之所以惨淡,是通常一个人乞求,另一个人却不施舍

凤凰网友:心不亡wenod∕
评论:活在自己的心里,不要活在别人的眼里。

其它网友:偏心   ■
评论:闭上眼睛,我看到了我的前途

淘宝网友:㏒° 多情mmmm
评论:八戒,别以为你站在路灯下就是夜明猪了

天涯网友:煙抽黑了心
评论:何为女流氓?答曰:思想上的女流氓。生活上的好姑娘。外形上的柔情少女。心理上的变形金刚……

本网网友:夠鐘死心孒
评论:人生如同故事,重要的并不是有多长,而是在有多好。

腾讯网友:爱情° love
评论:你打扮成这样,是对这个世界有什么不满吗?

猫扑网友:A monologue. 独白。
评论:世界上最遥远的距离,莫过于周一到周五。

百度网友:゛风骚, - /ov3
评论:对于男人而言,前女友就好象是亲生的,后女友就像是领养的。

新闻转自网络媒体,如有侵权,请与我们联系:1160322105@qq.com责编:admin